An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9190-9198

  Magnusson, Cecilia ^a   Ehrnström, Roy ^a   Olsen, Jørgen ^b   Sjölander, Anita ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ARACHIDONATE 5 LIPOXYGENASE; BUTYRIC ACID; CASPASE 3; CYCLOOXYGENASE 2; CYSTEINYL LEUKOTRIENE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; KI 67 ANTIGEN; LEUKOTRIENE RECEPTOR; PEPTIDOLEUKOTRIENE; PROTEIN BAX; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOCARCINOMA; APOPTOSIS; CACO-2 CELLS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; G0 PHASE; HUMANS; MEMBRANE PROTEINS; RECEPTORS, LEUKOTRIENE;

EID: 35148834706     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0771     Document Type: Article

References (48)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
2. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789-93.
3. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000;275:30531-6.
4. Hamm HE. The many faces of G protein signaling. J Biol Chem 1998;273:669-72.
5. Goetzl EJ. Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands. FASEB J 2007;21:638-42.
6. Bkaily G, Sleiman S, Stephan J, et al. Angiotensin II AT1 receptor internalization, translocation and de novo synthesis modulate cytosolic and nuclear calcium in human vascular smooth muscle cells. Can J Physiol Pharmacol 2003;81:274-87.
7. Nielsen CK, Campbell JI, Öhd JF, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 2005;65:732-42.
8. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5.
9. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000;274:316-22.
10. Sjöström M, Johansson AS, Schröder O, Qiu H, Palmblad J, Haeggström JZ. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:e37-41.
11. Hu H, Chen G, Zhang JM, et al. Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors. Acta Pharmacol Sin 2005;26:685-90.
12. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007;27:469-527.
13. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 2000;58:1601-8.
14. Dahlen SE, Haeggström JZ, Samuelsson B, Rabe KF, Leff AR. Leukotrienes as targets for treatment of asthma and other diseases. Current basic and clinical research. Am J Respir Crit Care Med 2000;161:S1.
15. Stenson WF. Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol Suppl 1990;172:13-8.
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
17. Hope ME, Hold GL, Kain R, El-Omar EM. Sporadic colorectal cancer - role of the commensal microbiota. FEMS Microbiol Lett 2005;244:1-7.
18. Campbell S, Ghosh S. Ulcerative colitis and colon cancer: strategies for cancer prevention. Dig Dis 2002;20:38-48.
19. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
20. Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988;95:668-75.
21. Heuschen UA, Heuschen G, Autschbach F, Allemeyer EH, Herfarth C. Adenocarcinoma in the ileal pouch: late risk of cancer after restorative proctocolectomy. Int J Colorectal Dis 2001;16:126-30.
22. Öhd JF, Wikström K, Sjölander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 2000;119:1007-18.
23. Paruchuri S, Sjölander A. Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal Epithelial cell line Int 407. J Biol Chem 2003;278:45577-85.
24. Paruchuri S, Broom O, Dib K, Sjölander A. The proinflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem 2005;280:13538-44.
25. Öhd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H, Sjölander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003;124:57-70.
26. Paruchuri S, Mezhybovska M, Juhas M, Sjölander A. Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells. Oncogene 2006;25:6660-5.
27. Mezhybovska M, Wikström K, Öhd JF, Sjölander A. The inflammatory mediator leukotriene D4 induces hcatenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J Biol Chem 2006;281:6776-84.
28. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002;277:11617-20.
29. Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 1984;44:3961-9.
30. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 2002;132:1012-7.
31. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323-32.
32. Hossain Z, Konishi M, Hosokawa M, Takahashi K. Effect of polyunsaturated fatty acid-enriched phosphatidylcholine and phosphatidylserine on butyrateinduced growth inhibition, differentiation and apoptosis in Caco-2 cells. Cell Biochem Funct 2006;24:159-65.
33. Parhamifar L, Jeppsson B, Sjölander A. Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells. Carcinogenesis 2005;26:1988-98.
34. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991;67:1169-79.
35. Peterson MD, Mooseker MS. Characterization of the enterocyte-like brush border cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco-2. J Cell Sci 1992;102:581-600.
36. Maroux S, Coudrier E, Feracci H, Gorvel JP, Louvard D. Molecular organization of the intestinal brush border. Biochimie 1988;70:1297-306.
37. Wang Q, Wang X, Hernandez A, Kim S, Evers BM. Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology 2001;120:1381-92.
38. Olsen L, Bressendorff S, Troelsen JT, Olsen J. Differentiation-dependent activation of the human intestinal alkaline phosphatase promoter by HNF-4 in intestinal cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G220-6.
39. Jans DA, Xiao CY, Lam MH. Nuclear targeting signal recognition: a key control point in nuclear transport? BioEssays 2000;66:532-44.
40. Servant MJ, Tenoever B, Lin R. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res 2002;22:49-58.
41. Wang J, Peng Y, Sun YW, et al. All-trans retinoic acid induces XAF1 expression through an IFN regulatory factor-1 element in colon cancer. Gastroenterology 2006;130:747-58.
42. Bouker KB, Skaar TC, Fernandez DR, et al. IFN regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, fulvestrant). Cancer Res 2004;64:4030-9.
43. Bouker KB, Skaar TC, Riggins RB, et al. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 2005;26:1527-35.
44. Yano H, Iemura A, Haramaki M, et al. Interferon α receptor expression and growth inhibition by IFNα in human liver cancer cell lines. Hepatology 1999;29:1708-17.
45. Zweibaum A, Hauri HP, Sterchi E, et al. Immunohistological evidence, obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons. Int J Cancer 1984;34:591-8.
46. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999;274:23679-82.
47. Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, Nilbert M. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004;111:921-8.
48. Basil CF, Zhao Y, Zavaglia K, et al. Common cancer biomarkers. Cancer Res 2006;66:2953-61.